+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 314 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating GNT0004, a gene therapy using a recombinant adeno-associated viral vector designed to deliver a shortened but functional dystrophin gene to treat Duchenne muscular dystrophy DMD in boys. DMD is caused by mutations in the dystrophin gene, leading to muscle damage from lack of this key protein. This therapy aims to slow disease progression by producing dystrophin in heart and skeletal muscles. The study has three parts. Part 1 involved testing two doses of GNT0004 in five boys to determine the best dose with acceptable safety. Part 2 is a randomized, blinded phase lasting 18 months where participants receive either GNT0004 or a placebo after 18 months, those on placebo switch to GNT0004 and vice versa. Part 3 is a long-term follow-up lasting up to five years to monitor safety and treatment effects in all participants who received GNT0004. Participants undergo assessments including muscle biopsies, blood tests, MRI scans, and functional tests like the North Star Ambulatory Assessment, performed at various times throughout the study. Researchers monitor safety by tracking adverse events and immune responses. Long-term follow-up includes measuring muscle function and respiratory capacity over five years. The study involves ambulant boys aged 6 to 10 years with confirmed DMD who meet specific health criteria.

Age: 6Years - 10YearsMALEPhase 2Phase 3
14 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
P

Actively Recruiting

Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.

Age: 18Years +All GendersPhase 3
111 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations

1-10 of 314

1